Plasma soluble lectin-like oxidized low-density lipoprotein receptor-1 acts as a new biomarker for NSTEMI and STEMI patients

OBJECTIVE: The diagnostic significance of plasma soluble lectin-like oxidized low-density lipoprotein receptor-1(sLOX-1) for non-ST segment elevated myocardial infarction (NSTEMI) and ST segment elevated myocardial infarction (STEMI) were explored by this study. METHODS: In this study, 107 acute NSTEMI, 223 acute STEMI and 107 healthy subjects, and hypoxic (1%02) ventricular cardiomyocytes H9c2 were used. RESULTS: The significantly up-regulated plasma sLOX-1 levels in acute NSTEMI and STEMI patients compared to healthy subjects (p<0.001). Both male and female NSTEMI and STEMI groups had remarkably higher concentrations of plasma sLOX-1 levels than controls (p<0.001). The circulating levels of sLOX-1 expression obviously elevated in elderly aging (60–75 years) than younger aging (30–45 years) both male and female in healthy subjects as well as NSTEMI and STEMI (p<0.001). Altered levels of sLOX-1 in blood plasma revealed a significant discrimination with high sensitivity and specificity between healthy with NSTEMI and STEMI subjects with AUC= 0.916 and AUC= 0.925 respectively. Moreover, LOX-1 levls were highly released from 6hour, 12hour and 18hour hypoxic injured H9c2 cells than normoxic cell (p<0.001), reflected circulating plasma sLOX-1 in AMI patients. CONCLUSION: Elevated levels of plasma sLOX-1concentrations might be used as a clinical biomarker for early recognition of NSTEMI and STEMI patients. Multicenter larger scale studies are necessary before use in clinical practice.